Marker Therapeutics, Inc. (MRKR) stock
MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.85+0.02 (+1.98%)
Close on Nov 18, 2026Market cap $14.23MP/E –Yield –
Marker Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Marker Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$10.71M. For fiscal 2025 it was -$12.89M. The highest annual figure on record is -$2.66M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.89M | – |
| FY2024 | Dec 31, 2024 | -$11.12M | – |
| FY2023 | Dec 31, 2023 | -$14.58M | – |
| FY2022 | Dec 31, 2022 | -$19.79M | – |
| FY2021 | Dec 31, 2021 | -$39.48M | – |
| FY2020 | Dec 31, 2020 | -$28.89M | – |
| FY2019 | Dec 31, 2019 | -$22.53M | – |
| FY2018 | Dec 31, 2018 | -$148.17M | – |
| FY2017 | Dec 31, 2017 | -$11.48M | – |
| FY2016 | Dec 31, 2016 | -$8.49M | – |
| FY2015 | Dec 31, 2015 | -$6.16M | – |
| FY2014 | Dec 31, 2014 | -$3.37M | – |
| FY2013 | Dec 31, 2013 | -$2.66M | – |
| FY2011 | Dec 31, 2011 | -$3.32M | – |
| FY2010 | Dec 31, 2010 | -$5.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.96M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.94M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.31M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.27M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.76M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.65M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.87M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.20M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.68M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.99M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.39M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.42M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.59M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.72M | – |
| Q2 FY2016 | Jun 30, 2016 | -$2.43M | – |
See a number that looks wrong?